Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

IN10018 Thérapie combinée dans le NSCLC avancé avec mutation EGFR

9 novembre 2026 mis à jour par: InxMed (Shanghai) Co., Ltd.

Un essai clinique multicentrique, ouvert, de phase Ib/II pour évaluer l'innocuité, la tolérance, la pharmacocinétique et l'efficacité anti-tumorale de l'IN10018 combiné à l'EGFR-TKI de troisième génération chez les patients atteints d'un CPNPC avancé à mutation EGFR-positive

This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Description détaillée

This study includes 2 parts: Phase Ib-Dose Confirmation and Phase II-Dose Expansion. And 3 cohorts are set up in this study as cohort 1 to enroll subjects currently accepting third-generation EGFR-TKI (Furmonertinib is proposed) as first-line treatment, cohort 2 to enroll subjects who previously accepted third-generation EGFR-TKI treatment and 1-2 lines chemotherapy, and cohort 3 to enroll treatment-naive advanced EGFR mutation-positive NSCLC subjects.

The phase Ib-dose confirmation part will be conducted in cohort 2 and aim to determine the recommended phase II dose (RP2D) of IN10018 in combination with Furmonertinib. Phase II-Dose Expansion part will be conducted in cohort 1-3 and further explore the antitumor efficacy, safety and PK of IN10018 in combination with Furmonertinib in subjects with previously-treated or naïve advanced EGFR mutation-positive NSCLC.

Type d'étude

Interventionnel

Inscription (Estimé)

110

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Shanghai, Chine
        • Shanghai Pulmonary Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria

  1. Be able to understand and be willing to sign informed consent.

  2. Male or female aged ≥ 18 years old at the time of signing informed consent.

  3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC, who is not suitable for radical surgery or radiotherapy.

  4. Documented EGFR mutations known to be associated with EGFR-TKI sensitivity, including Ex19del or L858R. Except for EGFR-TKI sensitive mutation, coexisting with other EGFR mutation types such as T790M can be allowed.

  5. Prior systemic antitumor therapy allowed are listed as follows:

    • Cohort 1: Subjects who are on the treatment of Furmonertinib as the first-line treatment setting.
    • Cohort 2: Subjects failed in third-generation EGFR-TKI treatment and also failed in or were intolerant to 1-2 lines of chemotherapy.
    • Cohort 3: subjects who haven't accepted any systemic therapy before. Prior adjuvant or neoadjuvant chemotherapy is permitted if an interval from the lost dose of adjuvant or neoadjuvant chemotherapy to the first documented PD is >6 months.
  6. Measurable lesions at baseline according to RECIST 1.1 criteria.

  7. Has an ECOG performance status of 0 or 1.

  8. Estimated life expectancy is more than 3 months.

  9. Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to the first dose of study treatment/randomization.

Exclusion Criteria

  1. Have experienced major surgical procedures or major trauma within 28 days prior to the first dose of study treatment/randomization.

  2. Have received the following prior systemic antitumor therapy:

    • Cohort 1: Have received chemotherapy, target therapy besides Furmonertinib, immunotherapy, biological therapy, and other antitumor drugs.
    • Cohort 2: Have received chemotherapy, targeted therapy, immunotherapy, biological therapy, and other antitumor drugs within 28 days prior to the first dose of study treatment.
    • Cohort 3: Have received systemic antitumor therapy for locally-advanced or metastatic NSCLC including chemotherapy, target therapy, immunotherapy, biotherapy, etc.
  3. Cohort 2 only: Presence of other gene mutations, including ALK mutation, MET amplification, HER2 amplification, RAS mutation, etc. after progression on prior third-generation EGFR-TKI treatment.

  4. Cohort 3 only:Has received the treatment of EGFR-TKI。

  5. Prior FAK inhibitors treatment.

  6. Have received systemic administration of potent inhibitors/inducers of CYP3A4, or P-gp inhibitors within 14 days prior to the first dose of treatment/randomization or are expected to receive systemic administration of these drugs during study treatment.

  7. Has received radiotherapy for study disease or radiotherapeutic area covered for more than 30% of the bone marrow within 28 days prior to the first dose of study treatment/randomization.

  8. Has had interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring steroid therapy; or diagnosis of clinically active ILD during the screening period.

  9. Has a prior history of other malignancy within 3 years prior to signing informed consent.

  10. Has known symptoms of spinal cord compression, active central nervous system (CNS) metastases, and/or carcinomatous meningitis.

  11. Has a history of severe cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment/randomization.

  12. Has known uncontrollable pleural effusion, pericardial effusion, and ascites.

  13. Has hemoptysis within 1 month prior to the first dose of study treatment/randomization with a blood volume of ≥2.5 mL every time or expected to require continuous hemostasis therapy during the study treatment.

  14. Has active infections that are poorly controlled by systemic treatment.

  15. Has active tuberculosis.

  16. Known allergy, hypersensitivity or intolerance to IN10018 and/or third-generation EGFR-TKI, or their ingredients.

  17. Pregnant or lactating women.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Experimental Group in cohort 1, cohort 2, and cohort 3

IN10018+Furmonertinib

orally taken once daily

Autres noms:
  • BI 853520

orally taken once daily

Comparateur actif: Control Group in cohort 3

Furmonertinib

orally taken once daily

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Recommended phase II dose (RP2D) of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced EGFR mutation-positive NSCLC.
Délai: 3 years

Evaluate the number of patients with dose-limited toxicities (DLTs); Determine the RP2D of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced NSCLC.

3 years
ORR of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced EGFR mutation-positive NSCLC.
Délai: 3 years

Defined as the proportion of subjects with complete response (CR) or partial response (PR)

3 years
Tumor Shrinkage Rate (TSR) of IN10018 in combination with third-generation EGFR-TKI in cohort 3 of advanced treatment-naive EGFR mutation-positive NSCLC.
Délai: 3 years

Defined as the percentage of subjects with the best shrinkage rate of target lesions ≥ 70% and simultaneously with a best response of partial response (PR) or complete response (CR).

3 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
PFS of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Délai: 3 years

Defined as the time from the first dose of study treatment/randomization to first documentation of disease progression or to death due to any cause, whichever comes first.

3 years
DOR of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Délai: 3 years

Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.

3 years
DCR of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Délai: 3 years

Defined as the proportion of patients with CR, PR, or stable disease (SD).

3 years
OS of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Délai: 3 years

Defined as the time from the first dose of study treatment/randomization to the date of death due to any cause.

3 years
Number of patients with adverse event
Délai: 3 years

The number of participants who experienced AEs is presented.

3 years
PK: AUC of IN10018 following single dose administration and at steady state
Délai: 3 years

Area under the concentration-time curve (AUC)

3 years
PK: Cmax of IN10018 following single dose administration and at steady state
Délai: 3 years

Maximum concentration (Cmax)

3 years
PK:Ctrough of IN10018 following single dose administration and at steady state
Délai: 3 years

Trough concentration (Ctrough)

3 years
PK:Tmax of IN10018 following single dose administration and at steady state
Délai: 3 years

Time to Cmax (Tmax)

3 years
PK:t1/2 of IN10018 following single dose administration and at steady state
Délai: 3 years

Elimination half-life (t1/2).

3 years
PK:CL/F of IN10018 following single dose administration and at steady state
Délai: 3 years

apparent clearance (CL/F)

3 years
PK:Vd/F of IN10018 following single dose administration and at steady state
Délai: 3 years

Apparent volume of distribution (Vd/F)

3 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Caicun Zhou, Shanghai Pulmonary Hospital, Shanghai, China

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

13 juillet 2023

Achèvement primaire (Réel)

20 septembre 2025

Achèvement de l'étude (Estimé)

31 décembre 2026

Dates d'inscription aux études

Première soumission

8 août 2023

Première soumission répondant aux critères de contrôle qualité

8 août 2023

Première publication (Réel)

16 août 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • IN10018-014

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner